RxDoctor Payments Data

Richard Foley, MD

Nephrology · Houston, TXNPI 1083699383

Payments from drug & device makers

$4,967in general payments, 2019–2025

Across 236 payments — averaging $21.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Mallinckrodt Hospital Products Inc.$738
  • Vifor Pharma, Inc.$696
  • Otsuka America Pharmaceutical, Inc.$486
  • Novartis$322
  • Calliditas Therapeutics US Inc.$239
  • plus $942 from 12 others

What the payments were for

  • Food & beverage$4,947100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,967 in reported general payments places this provider in the 70th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas

Medicare billing

Part B allowed, 2024
$131,629
Medicare patients
374
Services billed
4,004

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol143$96,190
ProcritEpoetin Alfa100$67,440
JardianceEmpagliflozin59$45,060
Sevelamer Carbonate27$8,784
Calcitriol256$5,515
Nifedipine ErNifedipine69$2,738
Potassium Citrate ErPotassium Citrate30$2,604
Losartan Potassium166$2,252
Bumetanide44$1,845
Carvedilol174$1,467
Spironolactone136$1,423
Calcium Acetate16$1,403
Midodrine Hcl13$1,235
Doxazosin Mesylate58$1,210
Lisinopril127$1,200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$1,543$96,190143 claims
Boehringer IngelheimJardiance$15$45,06059 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,070 nephrology providers in Texas.

Other nephrology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →